Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers

Blood

Volumn 118, Issue 4, 2011, Pages 955-964

  Sáez Cirión, Asier ^a   Hamimi, Chiraz ^a   Bergamaschi, Anna ^a   David, Annie ^a   Versmisse, Pierre ^a   Mélard, Adeline ^b   Boufassa, Faroudy ^c   Barré Sinoussi, Françoise ^a   Lambotte, Olivier ^c,d   Rouzioux, Christine ^b,e   Pancino, Gianfranco ^a  

^a INSTITUT PASTEUR   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c BICÊTRE HOSPITAL   (France)

^d INSERM   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEIN P21;

ARTICLE; CD4+ T LYMPHOCYTE; CELL TYPE; CONTROLLED STUDY; DISEASE PREDISPOSITION; EX VIVO STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; MACROPHAGE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 79961008229     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-12-327106     Document Type: Article

References (53)

1. Lambotte O, Boufassa F, Madec Y, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis. 2005;41(7):1053-1056. (Pubitemid 41368233)
2. Saez-Cirion A, Pancino G, Sinet M, Venet A, Lambotte O. HIV controllers: how do they tame the virus? Trends Immunol. 2007;28(12):532-540.
3. Dinoso JB, Kim SY, Siliciano RF, Blankson JN. A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. Clin Infect Dis. 2008;47(1):102-104. (Pubitemid 351920594)
4. Julg B, Pereyra F, Buzon MJ, et al. Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin Infect Dis. 2010;51(2):233-238.
5. Hersperger AR, Pereyra F, Nason M, et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog. 2010;6(5):e1000917.
6. Migueles SA, Osborne CM, Royce C, et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity. 2008;29(6):1009-1021.
7. Saez-Cirion A, Lacabaratz C, Lambotte O, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A. 2007;104(16):6776-6781. (Pubitemid 47175577)
8. Emu B, Sinclair E, Hatano H, et al. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol. 2008;82(11):5398-5407. (Pubitemid 351705247)
9. Pereyra F, Addo MM, Kaufmann DE, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis. 2008;197(4):563-571. (Pubitemid 351321534)
10. Saez-Cirion A, Sinet M, Shin SY, et al. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol. 2009;182(12):7828-7837.
11. Okulicz JF, Marconi VC, Landrum ML, et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis. 2009;200(11):1714-1723.
12. Goujard C, Chaix ML, Lambotte O, et al. Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established? Clin Infect Dis. 2009;49(6):982-986.
13. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86(3):367-377. (Pubitemid 26272077)
14. Saez-Cirion A, Versmisse P, Truong LX, et al. Persistent resistance to HIV-1 infection in CD4 T cells from exposed uninfected Vietnamese individuals is mediated by entry and post-entry blocks. Retrovirology. 2006;3:81.
15. Kirchhoff F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe. 2010;8(1):55-67.
16. Asada M, Yamada T, Ichijo H, et al. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 1999;18(5):1223-1234. (Pubitemid 29110307)
17. Harper JW AG, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805-816. (Pubitemid 23346377)
18. Bergamaschi A, David A, Le Rouzic E, Nisole S, Barre-Sinoussi F, Pancino G. The CDK inhibitor p21Cip1/WAF1 is induced by FcgammaR activation and restricts the replication of human immunodeficiency virus type 1 and related primate lentiviruses in human macrophages. J Virol. 2009;83(23):12253-12265.
19. Zhang J SD, Crumpaker CS. Primitive hematopoietic cells resist HIV-1 infection via p21Waf1/Cip1/Sdi1 J Clin Invest. 2007;117:473-481.
20. Rabi SA, O'Connell KA, Nikolaeva D, et al. Unstimulated primary CD4+ T cells from HIV type 1 positive elite suppressors are fully susceptible to HIV-1 entry and productive infection. J Virol. 2011;85(2):979-986.
21. Begaud E, Chartier L, Marechal V, et al. Reduced CD4 T cell activation and in vitro susceptibility to HIV-1 infection in exposed uninfected Central Africans. Retrovirology. 2006;3:35.
22. Cowan S, Hatziioannou T, Cunningham T, Muesing MA, Gottlinger HG, Bieniasz PD. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc Natl Acad Sci U S A. 2002;99(18):11914-11919. (Pubitemid 34994498)
23. Munk C, Brandt SM, Lucero G, Landau NR. A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc Natl Acad Sci U S A. 2002;99(21):13843-13848. (Pubitemid 35215468)
24. Avettand-Fenoel V, Chaix ML, Blanche S, et al. LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol. 2009;81(2):217-223.
25. David A, Saez-Cirion A, Versmisse P, et al. The engagement of activating FcgammaRs inhibits primate lentivirus replication in human macrophages. J Immunol. 2006;177(9):6291-6300. (Pubitemid 44628847)
26. O'Doherty U, Swiggard WJ, Malim MH. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol. 2000;74(21):10074-10080.
27. Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology. 1995;206(2):935-944.
28. Sáez-Cirión A, Nicola MA, Pancino G, Shorte SL. Quantitative real-time analysis of HIV-1 gene expression dynamics in single living primary cells. Biotechnol J. 2006;1(6):682-689.
29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-408. (Pubitemid 34164012)
30. Salkowitz JR, Purvis SF, Meyerson H, et al. Characterization of high-risk HIV-1 seronegative hemophiliacs. Clin Immunol. 2001;98(2):200-211.
31. Sourisseau M, Sol-Foulon N, Porrot F, Blanchet F, Schwartz O. Inefficient human immunodeficiency virus replication in mobile lymphocytes. J Virol. 2007;81(2):1000-1012. (Pubitemid 46067924)
32. Avettand-Fenoel V, Prazuck T, Hocqueloux L, et al. HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors. AIDS. 2008;22(14):1880-1882.
33. Ghosn J, Deveau C, Chaix ML, et al. Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort. J Antimicrob Chemother. 2010;65(4):741-748.
34. Rouzioux C, Hubert J-B, Burgard M, et al. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+T cell counts. J Infect Dis. 2005;192(1):46-55. (Pubitemid 40863856)
35. Piketty C, Weiss L, Assoumou L, et al. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir. J Med Virol. 2010;82(11):1819-1828.
36. Xie J, Lu W, Samri A, et al. Distinct differentiation profiles of HIV-Gag and Nef-specific central memory CD8+ T cells associated with HLA-B57/5801 and virus control. AIDS. 2010;24(15):2323-2329.
37. Betts MR, Nason MC, West SM, et al. HIV non-progressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006;107(12):4781-4789. (Pubitemid 43882629)
38. Nishimura Y, Sadjadpour R, Mattapallil JJ, et al. High frequencies of resting CD4+ T cells containing integrated viral DNA are found in rhesus macaques during acute lentivirus infections. Proc Natl Acad Sci U S A. 2009;106(19):8015-8020.
39. Aquaro S, Calio R, Balzarini J, Bellocchi MC, Garaci E, Perno CF. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res. 2002;55(2):209-225. (Pubitemid 34718126)
40. Orenstein JM, Fox C, Wahl SM. Macrophages as a source of HIV during opportunistic infections. Science. 1997;276(5320):1857-1861.
41. Sharova N, Swingler C, Sharkey M, Stevenson M. Macrophages archive HIV-1 virions for dissemination in trans. EMBO J. 2005;24(13):2481-2489. (Pubitemid 41032598)
42. Hirsch V, Sharkey M, Brown C, et al. Vpx is required for dissemination and pathogenesis of SIV(SM) PBj: evidence of macrophage-dependent viral amplification. Nat Med. 1998;4(12):1401-1408. (Pubitemid 28553463)
43. Graf EH, Mexas AM, Yu JJ, et al. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog. 2011;7(2):e1001300.
44. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003;424(6944):99-103. (Pubitemid 36834849)
45. Mbisa JL, Barr R, Thomas JA, et al. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol. 2007;81(13):7099-7110. (Pubitemid 46986646)
46. Jin X, Brooks A, Chen H, Bennett R, Reichman R, Smith H.APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J Virol. 2005;79(17):11513-11516. (Pubitemid 41170693)
47. Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN. Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol. 2008;82(6):3125-3130. (Pubitemid 351329200)
48. Loke P, Favre D, Hunt PW, et al. Correlating cellular and molecular signatures of mucosal immunity that distinguish HIV controllers from noncontrollers. Blood. 2010;115(15):e20-32.
49. Chen H, Li C, Huang J, et al. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest. 2011;121(4):1549-1560.
50. Wu W, Kehn-Hall K, Pedati C, et al. Drug 9AA reactivates p21/Waf1 and Inhibits HIV-1 progeny formation. Virol J. 2008;5:41.
51. Arias CF, Ballesteros-Tato A, Garcia MI, et al. p21CIP1/WAF1 controls proliferation of activated/memory T cells and affects homeostasis and memory T cell responses. J Immunol. 2007;178(4):2296-2306. (Pubitemid 46233428)
52. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther. 2002;1(8):639-649.
53. van Grevenynghe J, Procopio FA, He Z, et al. Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection. Nat Med. 2008;14(3):266-274. (Pubitemid 351347916)